TT
The startup develops targeted therapeutics for myelodysplastic syndrome and acute myeloid leukemia, utilizing a platform that focuses on solid tumors, including gastric cancer. Their approach aims to enhance treatment outcomes for patients by evaluating the efficacy of Tomaralimab-based therapies.
Updated 2 months ago
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops targeted therapeutics for myelodysplastic syndrome and acute myeloid leukemia, utilizing a platform that focuses on solid tumors, including gastric cancer. Their approach aims to enhance treatment outcomes for patients by evaluating the efficacy of Tomaralimab-based therapies.